Methodological Concerns Assessing Tenecteplase's Safety

Ann Emerg Med. 2024 Aug;84(2):227-228. doi: 10.1016/j.annemergmed.2024.02.021.
No abstract available

Publication types

  • Letter

MeSH terms

  • Fibrinolytic Agents* / adverse effects
  • Fibrinolytic Agents* / therapeutic use
  • Humans
  • Tenecteplase* / therapeutic use
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Tenecteplase
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator